Acorda Therapeutics (ACOR) Misses Q4 EPS by 102c

FREE Breaking News Alerts from StreetInsider.com!

E-mail Address

StreetInsider.com Top Tickers, 8/17/2026

1. SPY
2. EYPT
3. NVDA
4. USO
5. GNK
6. PLUR
7. MU
8. ARGX
9. AZN
10. SPCX

Go back to Acorda Therapeutics (ACOR) Misses Q4 EPS by 102c

Acorda Therapeutics Provides Business Update and Reports Fourth Quarter and Full Year 2020 Financial Results

March 4, 2021 4:01 PM EST

Sale of Manufacturing Operations to Catalent with net proceeds of ~$74 million Annual operating expenses cut by ~$40 million via sale, restructuring, and other reductions Total 2021 non-GAAP operating expense expected to be $130-$140 million1 AMPYRA® (dalfampridine) Extended Release Tablets, 10 mg 2021 net revenue expected to be $75-$85 million INBRIJA® (levodopa inhalation powder) 2020 net revenue $24 million AMPYRA 2020 net revenue $99 million

ARDSLEY, N.Y.--(BUSINESS WIRE)-- Acorda Therapeutics, Inc. (Nasdaq: ACOR) today provided a business update and reported its financial results for the fourth quarter and full... More